Topline data were announced from 2 phase 3 trials evaluating MR-107A-02 for the treatment of moderate to severe acute pain.

Topline data were announced from two phase 3 trials evaluating MR-107A-02 for the treatment of moderate to severe acute pain.

Topline data were announced from two phase 3 studies evaluating MR-107A-02 for the treatment of moderate to severe acute pain.

Viatris Inc (NASDAQ:VTRS) announced positive data for Phase 3 studies of novel fast-acting meloxicam for moderate to severe acute pain, highlighting its potential as a non-opioid treatment option. The ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Top-line results from two pivotal Phase III trials found that MR-107A-02 significantly reduced pain intensity following ...

Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsBill Szablewski - Head of Capital MarketsScott Smith ...

Viatris (NASDAQ:VTRS) stock rises 5% premarket as Phase 3 trials show success for non-opioid pain therapy, meloxicam as a ...

Viatris' fast-acting form of generic pain drug meloxicam met the main goals of two late-stage studies, the company said on Thursday, adding that it would seek the US FDA's marketing approval for the ...

“Over the past decade, there has been a major shift in the way we treat pain after joint replacement…The findings from this study demonstrate that surgeons are utilizing a multimodal approach ...

Medically reviewed by David Ozeri, MD Ibuprofen and meloxicam are both nonsteroidal anti-inflammatory drugs (NSAIDs) that ...